Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022

Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on mental health and oncology treatments, announced that CEO Dr. Joseph Tucker will participate in two upcoming investor conferences. The first is Citi's Psychedelic Drug Call Series on February 8, 2022, at 10:00 a.m. ET, followed by the Aegis Capital Corp. Virtual Conference on February 25, 2022, at 3:00 p.m. ET. Enveric specializes in leveraging psychedelic-derived molecules and synthetic cannabinoids for innovative therapeutic solutions targeting conditions like cancer-related distress and PTSD.

NAPLES, Fla., Jan. 27, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming investor conferences:

Citi's Psychedelic Drug Call Series
Tuesday, February 8^th at 10:00 a.m. ET
A fireside chat hosted by Neena Bitritto-Garg, Citi's Biotech analyst.

Aegis Capital Corp. Virtual Conference
Friday, February 25^th at 3:00 p.m. ET
To access the event, please download and import the following iCalendar (.ics) files to your calendar system: Aegis Virtual Conference Calendar.

For more information about the events, or to schedule a one-on-one meeting with Enveric's management team, please contact your appropriate Citi or Aegis representative, respectively, or send an email to KCSA Strategic Communications at EnvericBio@kcsa.com.

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric's robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For more information, please visit www.enveric.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-february-2022-301469195.html

SOURCE Enveric Biosciences

FAQ

What conferences is Enveric Biosciences participating in February 2022?

Enveric Biosciences will participate in Citi's Psychedelic Drug Call Series on February 8, 2022, at 10:00 a.m. ET, and the Aegis Capital Corp. Virtual Conference on February 25, 2022, at 3:00 p.m. ET.

Who is presenting for Enveric Biosciences at the investor conferences?

Dr. Joseph Tucker, the CEO of Enveric Biosciences, will present at the upcoming investor conferences.

What is the focus of Enveric Biosciences' treatments?

Enveric Biosciences focuses on developing mental health and oncology treatments using psychedelic-derived molecules and synthetic cannabinoids.

What are the dates and times of the upcoming conferences for ENVB?

The Citi conference is on February 8, 2022, at 10:00 a.m. ET, and the Aegis conference is on February 25, 2022, at 3:00 p.m. ET.

How can I access the Aegis Capital Corp. Virtual Conference?

To access the Aegis Capital Corp. Virtual Conference, you can download the iCalendar (.ics) files provided by Enveric Biosciences.